Top

Published in:

01-11-2019 | Fibrinolytic Therapy

Research progress on the pathogenesis of CTEPH

Authors: Lu Yan, Xin Li, Zhihong Liu, Zhihui Zhao, Qin Luo, Qin Zhao, Qi Jin, Xue Yu, Yi Zhang

Published in: Heart Failure Reviews | Issue 6/2019

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is an established long-term complication of pulmonary thromboembolism (PTE). However, studies have shown that many patients with a definitive CTEPH diagnosis have no history of symptomatic PTE, suggesting that PTE is not the only cause of CTEPH. Despite extensive progress in research on pulmonary hypertension in recent years, due to a lack of relevant studies on the pathophysiology of CTEPH, implementing pulmonary endarterectomy (PEA) in patients has many challenges, and the prognosis of patients with CTEPH is still not optimistic. Therefore, revealing the pathogenesis of CTEPH would be of great significance for understanding the occurrence and development of CTEPH, developing relevant drug treatment studies and formulating intervention strategies, and may provide new preventive measures. This article summarizes the current research progress in CTEPH pathogenesis from the perspective of risk factors related to medical history, abnormal coagulation and fibrinolytic mechanisms, inflammatory mechanisms, genetic susceptibility factors, angiogenesis, in situ thrombosis, vascular remodeling, and other aspects.

Opitz C, Rosenkranz S, Ghofrani HA, Grünig E, Klose H, Olschewski H, Hoeper M (2016) ESC guidelines 2015 pulmonary hypertension: diagnosis and treatment. Dtsch Med Wochenschr 141(24):1764–1769PubMedCrossRef

Lang IM, Pesavento R, Bonderman D, Yuan JX (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 41(2):462–468PubMedCrossRef

Elwing JM, Vaidya A, Auger WR (2018) Chronic thromboembolic pulmonary hypertension: An Update. Clin Chest Med 39(3):605–620PubMedCrossRef

Gall H, Hoeper MM, Richter MJ, Cacheris W, Hinzmann B, Mayer E (2017) An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev 26(143):160121PubMedCrossRef

Tapson VF, Platt DM, Xia F, Teal SA, de la Orden M, Divers CH, Satler CA, Joish VN, Channick RN (2016) Monitoring for pulmonary hypertension following pulmonary embolism: the INFORM study. Am J Med 129(9):978–985 e972 PubMedCrossRef

Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P, Thromboembolic Pulmonary Hypertension Study Group (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350(22):2257–2264PubMedCrossRef

Yang S, Yang Y, Zhai Z, Kuang T, Gong J, Zhang S, Zhu J, Liang L, Shen YH, Wang C (2015) Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. J Thorac Dis 7(11):1927–1938PubMedPubMedCentral

Escribano-Subias P, Blanco I, Lopez-Meseguer M et al (2012) Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 40(3):596–603PubMedCrossRef

Fernandes T, Auger W, Fedullo P (2018) Epidemiology and risk factors for chronic thromboembolic pulmonary hypertension. Thromb Res 164:145–149PubMedCrossRef

10.

Woo K, Tse L, Tse C, Metreweli C, Vallance-Owen J (1988) The prevalence and pattern of pulmonary thromboembolism in the Chinese in Hong Kong. Int J Cardiol 20(3):373–380PubMedCrossRef

11.

Yang Y, Liang L, Zhai Z, He H, Xie W, Peng X, Wang C, on behalf of investigators for the National Cooperative Project for the Prevention and Treatment of PTE-DVT (2011) Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study. PLoS One 6(11):e26861PubMedPubMedCentralCrossRef

12.

Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D'Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jaïs X, Simonneau G (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124(18):1973–1981PubMedCrossRef

13.

Al-Naamani N, Espitia HG, Velazquez-Moreno H et al (2016) Chronic thromboembolic pulmonary hypertension: experience from a single center in Mexico. Lung 194(2):315–323PubMedPubMedCentralCrossRef

14.

Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81(2):151–158PubMedCrossRef

15.

Lewczuk J, Piszko P, Jagas J, Porada A, Sobkowicz B, Wrabec K, Wójciak S (2001) Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 119(3):818–823PubMedCrossRef

16.

Auger WR, Kim NH, Trow TK (2010) Chronic thromboembolic pulmonary hypertension. Clin Chest Med 31(4):741–758PubMedCrossRef

17.

Egermayer P, Peacock AJ (2000) Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 15(3):440–448PubMedCrossRef

18.

Lang IM, Marsh JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR (1993) Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 87(6):1990–2000PubMedCrossRef

19.

Lang IM, Marsh J, Moser K, Schleef R (1992) Presence of active and latent type 1 plasminogen activator inhibitor associated with porcine platelets. Blood 80(9):2269–2274CrossRefPubMed

20.

Fedullo PF, Auger WR, Kerr KM, Rubin LJ (2001) Chronic thromboembolic pulmonary hypertension. N Engl J Med 345(20):1465–1472PubMedCrossRef

21.

Pesavento R, Filippi L, Palla A, Visonà A, Bova C, Marzolo M, Porro F, Villalta S, Ciammaichella M, Bucherini E, Nante G, Battistelli S, Muiesan ML, Beltramello G, Prisco D, Casazza F, Ageno W, Palareti G, Quintavalla R, Monti S, Mumoli N, Zanatta N, Cappelli R, Cattaneo M, Moretti V, Corà F, Bazzan M, Ghirarduzzi A, Frigo AC, Miniati M, Prandoni P, SCOPE Investigators (2017) Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. Eur Respir J 49(5):1601980PubMedCrossRef

22.

Yamaki S, Ando M, Fukumoto Y, Higuchi Y, Kaneko K, Maeda K, Shimokawa H (2014) Histopathological examination by lung biopsy for the evaluation of operability and postoperative prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 78(2):476–482PubMedCrossRef

23.

Lang IM, Madani M (2014) Update on chronic thromboembolic pulmonary hypertension. Circulation 130(6):508–518PubMedCrossRef

24.

Edward JA, Mandras S (2017) An update on the management of chronic thromboembolic pulmonary hypertension. Curr Probl Cardiol 42(1):7–38PubMedCrossRef

25.

Miniati M, Monti S, Bottai M, Scoscia E, Bauleo C, Tonelli L, Dainelli A, Giuntini C (2006) Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 85(5):253–262CrossRef

26.

Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, Ageno W (2006) Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 130(1):172–175PubMedCrossRef

27.

Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV (2010) Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 95(6):970–975PubMedPubMedCentralCrossRef

28.

Poli D, Grifoni E, Antonucci E, Arcangeli C, Prisco D, Abbate R, Miniati M (2010) Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis 30(3):294–299PubMedCrossRef

29.

Guerin L, Couturaud F, Parent F et al (2014) Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 112(3):598–605PubMedCrossRef

30.

Otero R, Oribe M, Ballaz A, Jimenez D, Uresandi F, Nauffal D, Conget F, Rodriguez C, Elias T, Jara L, Cayuela A, Blanco I, Barberá J (2011) Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. Thromb Res 127(4):303–308PubMedCrossRef

31.

Dentali F, Donadini M, Gianni M, Bertolini A, Squizzato A, Venco A, Ageno W (2009) Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 124(3):256–258PubMedCrossRef

32.

Korkmaz A, Ozlu T, Ozsu S, Kazaz Z, Bulbul Y (2012) Long-term outcomes in acute pulmonary thromboembolism: the incidence of chronic thromboembolic pulmonary hypertension and associated risk factors. Clin Appl Thromb Hemost 18(3):281–288PubMedCrossRef

33.

Fedullo P, Kerr KM, Kim NH, Auger WR (2011) Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 183(12):1605–1613PubMedCrossRef

34.

Bonderman D, Wilkens H, Wakounig S, Schäfers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM (2009) Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 33(2):325–331PubMedCrossRef

35.

Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle P, Schönauer V, Exner M, Klepetko W, Kneussl M, Maurer G, Lang I (2005) Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93(3):512–516PubMedCrossRef

36.

Kim NH, Lang IM (2012) Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir Rev 21(123):27–31PubMedCrossRef

37.

Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343(7):457–462PubMedCrossRef

38.

Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin L, Kyrle P, Klepetko W, Maurer G, Lang I (2003) High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 90(3):372–376PubMedCrossRef

39.

Lisman T, de Groot PG, Meijers JC, Rosendaal FR (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105(3):1102–1105PubMedCrossRef

40.

Morris TA (2013) Why acute pulmonary embolism becomes chronic thromboembolic pulmonary hypertension: clinical and genetic insights. Curr Opin Pulm Med 19(5):422–429PubMed

41.

Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. J Cell Physiol 227(2):493–507PubMedPubMedCentralCrossRef

42.

Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, Wheaton E, Klein A, Arrowsmith J, Hall R, Jenkins D (2011) Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet 378(9800):1379–1387PubMedCrossRef

43.

Lang IM, Marsh JJ, Olman MA, Moser KM, Schleef RR (1994) Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 90(2):706–712PubMedCrossRef

44.

Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL Jr (2006) Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173(11):1270–1275PubMedPubMedCentralCrossRef

45.

Morris TA, Marsh JJ, Chiles PG, Magana MM, Liang NC, Soler X, DeSantis DJ, Ngo D, Woods VL (2009) High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 114(9):1929–1936PubMedPubMedCentralCrossRef

46.

Miniati M, Fiorillo C, Becatti M, Monti S, Bottai M, Marini C, Grifoni E, Formichi B, Bauleo C, Arcangeli C, Poli D, Nassi PA, Abbate R, Prisco D (2010) Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 181(9):992–996PubMedCrossRef

47.

Suntharalingam J, Goldsmith K, van Marion V, Long L, Treacy CM, Dudbridge F, Toshner MR, Pepke-Zaba J, Eikenboom JCJ, Morrell NW (2008) Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur Respir J 31(4):736–741PubMedCrossRef

48.

Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA (2003) Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 107(18):2326–2330PubMedCrossRef

49.

Kellermair J, Redwan B, Alias S, Jabkowski J, Panzenboeck A, Kellermair L, Winter MP, Weltermann A, Lang IM (2013) Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution. Blood 122(19):3376–3384PubMedCrossRef

50.

Bonderman D, Jakowitsch J, Redwan B, Bergmeister H, Renner MK, Panzenböck H, Adlbrecht C, Georgopoulos A, Klepetko W, Kneussl M, Lang IM (2008) Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 28(4):678–684PubMedCrossRef

51.

Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Bálint Z, Kwapiszewska G, Lang IM, Klepetko W, Olschewski H, Olschewski A (2014) Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J 44(4):951–962PubMedCrossRef

52.

Quarck R, Nawrot T, Meyns B, Delcroix M (2009) C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 53(14):1211–1218PubMedCrossRef

53.

Cohn DM, Roshani S, Middeldorp S (2007) Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost 33(6):573–581PubMedCrossRef

54.

Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G (2000) Thrombotic risk factors in pulmonary hypertension. Eur Respir J 15(2):395–399PubMedCrossRef

55.

Wong CL, Szydlo R, Gibbs S, Laffan M (2010) Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 21(3):201–206PubMedCrossRef

56.

Lotta LA, Tuana G, Yu J, Martinelli I, Wang M, Yu F, Passamonti SM, Pappalardo E, Valsecchi C, Scherer SE, Hale W IV, Muzny DM, Randi G, Rosendaal FR, Gibbs RA, Peyvandi F (2013) Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. J Thromb Haemost 11(7):1228–1239PubMedCrossRef

57.

Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W (1985) Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 37(1):89–101PubMedPubMedCentral

58.

Ma Q, Jacobi PM, Emmer BT, Kretz CA, Ozel AB, McGee B, Kimchi-Sarfaty C, Ginsburg D, Li JZ, Desch KC (2017) Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. Blood Adv 1(15):1037–1046PubMedPubMedCentralCrossRef

59.

Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR (2007) ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109(5):1998–2000PubMedCrossRef

60.

Newnham M, South K, Bleda M, Auger WR, Barberà JA, Bogaard H, Bunclark K, Cannon JE, Delcroix M, Hadinnapola C, Howard LS, Jenkins D, Mayer E, Ng C, Rhodes CJ, Screaton N, Sheares K, Simpson MA, Southwood M, Su L, Taboada D, Traylor M, Trembath RC, Villar SS, Wilkins MR, Wharton J, Gräf S, Pepke-Zaba J, Laffan M, Lane DA, Morrell NW, Toshner M (2019) The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. Eur Respir J 53(3):1801805PubMedPubMedCentralCrossRef

61.

Feng YX, Liu D, Sun ML, Jiang X, Sun N, Mao YM, Jing ZC (2014) BMPR2 germline mutation in chronic thromboembolic pulmonary hypertension. Lung 192(4):625–627PubMedCrossRef

62.

Ulrich S, Szamalek-Hoegel J, Hersberger M, Fischler M, Garcia JS, Huber LC, Grünig E, Janssen B, Speich R (2010) Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease. Respiration 79(4):279–287PubMedCrossRef

63.

Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O (2003) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47(3):149–161PubMed

64.

Waltham M, Burnand KG, Collins M, Smith A (2000) Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 32(5):988–996PubMedCrossRef

65.

Henke PK, Wakefield TW, Kadell AM, Linn MJ, Varma MR, Sarkar M, Hawley A, Fowlkes JB, Strieter RM (2001) Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 99(1):84–91PubMedCrossRef

66.

Yaoita N, Shirakawa R, Fukumoto Y, Sugimura K, Miyata S, Miura Y, Nochioka K, Miura M, Tatebe S, Aoki T, Yamamoto S, Satoh K, Kimura T, Shimokawa H, Horiuchi H (2014) Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 34(11):2486–2494PubMedCrossRef

67.

Moser KM, Bloor CM (1993) Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103(3):685–692PubMedCrossRef

68.

Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR (1994) Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 89(6):2715–2721PubMedCrossRef

69.

Sakao S, Tatsumi K (2013) Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective. Histol Histopathol 28(2):185–193PubMed

70.

Sakao S, Hao H, Tanabe N, Kasahara Y, Kurosu K, Tatsumi K (2011) Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respir Res 12:109PubMedPubMedCentralCrossRef

71.

Firth AL, Yao W, Ogawa A, Madani MM, Lin GY, Yuan JX (2010) Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Cell Physiol 298(5):C1217–C1225PubMedPubMedCentralCrossRef

72.

Zabini D, Nagaraj C, Stacher E, Lang IM, Nierlich P, Klepetko W, Heinemann A, Olschewski H, Bálint Z, Olschewski A (2012) Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS One 7(8):e43793PubMedPubMedCentralCrossRef

73.

Firth AL, Yau J, White A, Chiles PG, Marsh JJ, Morris TA, Yuan JXJ (2009) Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells. Am J Physiol Lung Cell Mol Physiol 296(6):L979–L986PubMedPubMedCentralCrossRef

74.

Rhodes CJ, Im H, Cao A, Hennigs JK, Wang L, Sa S, Chen PI, Nickel NP, Miyagawa K, Hopper RK, Tojais NF, Li CG, Gu M, Spiekerkoetter E, Xian Z, Chen R, Zhao M, Kaschwich M, del Rosario PA, Bernstein D, Zamanian RT, Wu JC, Snyder MP, Rabinovitch M (2015) RNA sequencing analysis detection of a novel pathway of endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 192(3):356–366PubMedPubMedCentralCrossRef

75.

Abdul-Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ, Wilkins MR (2010) Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 122(20):2058–2067PubMedCrossRef

76.

Hemnes AR, Trammell AW, Archer SL, Rich S, Yu C, Nian H, Penner N, Funke M, Wheeler L, Robbins IM, Austin ED, Newman JH, West J (2015) Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation. 131(4):401–409 discussion 409 PubMedCrossRef

Title: Research progress on the pathogenesis of CTEPH
Authors: Lu Yan
Xin Li
Zhihong Liu
Zhihui Zhao
Qin Luo
Qin Zhao
Qi Jin
Xue Yu
Yi Zhang
Publication date: 01-11-2019
Publisher: Springer US
Keywords: Fibrinolytic Therapy
Pulmonary Hypertension
Thrombosis
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Published in: Heart Failure Reviews / Issue 6/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-019-09802-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Research progress on the pathogenesis of CTEPH

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2019

Advances in targeted therapy for chronic thromboembolic pulmonary hypertension

Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors

Biomarkers in heart failure: the past, current and future

A review of fibroblast growth factor 21 in diabetic cardiomyopathy

Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target

Patients with high-dose diuretics should get ultrafiltration in the management of decompensated heart failure: a meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page